OneDrug, Toronto, ON, Canada.
Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, ON, M5S 3M2, Canada.
Cancer Chemother Pharmacol. 2024 Feb;93(2):89-105. doi: 10.1007/s00280-023-04575-y. Epub 2023 Aug 18.
ImmunoGen developed mirvetuximab soravtansine as an antibody-drug conjugate comprising of a humanized anti-folate receptor-α (FRα) monoclonal antibody of IgG1k subtype, a cleavable linker, and a cytotoxic payload, DM4. Mirvetuximab soravtansine was granted accelerated approval by the US FDA on November 14, 2022, for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens. The approval of mirvetuximab soravtansine represents a breakthrough for addressing the unmet medical needs of ovarian cancer, especially for up to 80% of patients who relapse and become resistant to platinum-based chemotherapy, resulting in poor prognosis and limited treatment options. However, it is my impression that addressing several pharmacological factors could improve the safety and efficacy of mirvetuximab soravtansine. This article summarizes the current pharmacological profile of mirvetuximab soravtansine and provides an expert opinion on pharmacological strategies for optimizing its safety and efficacy profile for the treatment of platinum-resistant ovarian cancer.
ImmunoGen 公司开发了 mirvetuximab soravtansine，这是一种抗体药物偶联物，由人源化抗叶酸受体-α（FRα）单克隆抗体 IgG1k 亚型、可切割接头和细胞毒性有效载荷 DM4 组成。2022 年 11 月 14 日，mirvetuximab soravtansine 获得美国 FDA 的加速批准，用于治疗 FRα 阳性、铂类耐药的上皮性卵巢癌、输卵管癌或原发性腹膜癌的成年患者，这些患者已经接受了 1-3 种先前的全身治疗方案。mirvetuximab soravtansine 的批准代表着满足卵巢癌未满足的医疗需求的突破，特别是对于多达 80%的复发并对铂类化疗产生耐药的患者，这些患者预后较差，治疗选择有限。然而，我认为解决几个药理学因素可以提高 mirvetuximab soravtansine 的安全性和疗效。本文总结了 mirvetuximab soravtansine 的当前药理学特征，并就优化其治疗铂类耐药卵巢癌的安全性和疗效特征的药理学策略提供了专家意见。
